Literature DB >> 26429975

MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.

Brian Kwok1, Jeff M Hall1, John S Witte2, Yin Xu1, Prashanti Reddy1, Keming Lin1, Rachel Flamholz1, Bashar Dabbas1, Aine Yung1, Jenan Al-Hafidh1, Emily Balmert1, Christine Vaupel1, Carlos El Hader1, Matthew J McGinniss1, Shareef A Nahas1, Julie Kines1, Rafael Bejar3.   

Abstract

Establishing a diagnosis in patients suspected of having a myelodysplastic syndrome (MDS) can be challenging and could be informed by the identification of somatic mutations. We performed a prospective study to examine the frequency and types of mutations encountered in 144 patients with unexplained cytopenias. Based on bone marrow findings, 17% were diagnosed with MDS, 15% with idiopathic cytopenias of undetermined significance (ICUS) and some evidence of dysplasia, and 69% with ICUS and no dysplasia. Bone marrow DNA was sequenced for mutations in 22 frequently mutated myeloid malignancy genes. Somatic mutations were identified in 71% of MDS patients, 62% of patients with ICUS and some dysplasia, and 20% of ICUS patients and no dysplasia. In total, 35% of ICUS patients carried a somatic mutation or chromosomal abnormality indicative of clonal hematopoiesis. We validated these results in a cohort of 91 lower-risk MDS and 249 ICUS cases identified over a 6-month interval. Mutations were found in 79% of those with MDS, in 45% of those with ICUS with dysplasia, and in 17% of those with ICUS without dysplasia. The spectrum of mutated genes was similar with the exception of SF3B1 which was rarely mutated in patients without dysplasia. Variant allele fractions were comparable between clonal ICUS (CCUS) and MDS as were mean age and blood counts. We demonstrate that CCUS is a more frequent diagnosis than MDS in cytopenic patients. Clinical and mutational features are similar in these groups and may have diagnostic utility once outcomes in CCUS patients are better understood.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2015        PMID: 26429975      PMCID: PMC4653764          DOI: 10.1182/blood-2015-08-667063

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients.

Authors:  T Schroeder; L Ruf; A Bernhardt; B Hildebrandt; M Aivado; C Aul; N Gattermann; R Haas; U Germing
Journal:  Ann Oncol       Date:  2010-05-03       Impact factor: 32.976

2.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Authors:  David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert
Journal:  Blood       Date:  2015-04-30       Impact factor: 22.113

Review 3.  The epidemiology of myelodysplastic syndromes.

Authors:  Mikkael A Sekeres
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

4.  Age-related clonal hematopoiesis associated with adverse outcomes.

Authors:  Siddhartha Jaiswal; Pierre Fontanillas; Jason Flannick; Alisa Manning; Peter V Grauman; Brenton G Mar; R Coleman Lindsley; Craig H Mermel; Noel Burtt; Alejandro Chavez; John M Higgins; Vladislav Moltchanov; Frank C Kuo; Michael J Kluk; Brian Henderson; Leena Kinnunen; Heikki A Koistinen; Claes Ladenvall; Gad Getz; Adolfo Correa; Benjamin F Banahan; Stacey Gabriel; Sekar Kathiresan; Heather M Stringham; Mark I McCarthy; Michael Boehnke; Jaakko Tuomilehto; Christopher Haiman; Leif Groop; Gil Atzmon; James G Wilson; Donna Neuberg; David Altshuler; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

5.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

Review 6.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

7.  Loss of the Y chromosome: an age-related or clonal phenomenon in acute myelogenous leukemia/myelodysplastic syndrome?

Authors:  Anna K Wong; Belle Fang; Ling Zhang; Xiuqing Guo; Stephen Lee; Rhona Schreck
Journal:  Arch Pathol Lab Med       Date:  2008-08       Impact factor: 5.534

8.  Molecular genetic evidence of Y chromosome loss in male patients with hematological disorders.

Authors:  Li-jun Zhang; Eun Sim Shin; Zhong-xing Yu; Shi-bo Li
Journal:  Chin Med J (Engl)       Date:  2007-11-20       Impact factor: 2.628

9.  Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface.

Authors:  Friedrich Wimazal; Christa Fonatsch; Renate Thalhammer; Ilse Schwarzinger; Leonhard Müllauer; Wolfgang R Sperr; John M Bennett; Peter Valent
Journal:  Leuk Res       Date:  2007-05-16       Impact factor: 3.156

10.  Mutational spectrum of adult T-ALL.

Authors:  Martin Neumann; Sebastian Vosberg; Cornelia Schlee; Sandra Heesch; Stefan Schwartz; Nicola Gökbuget; Dieter Hoelzer; Alexander Graf; Stefan Krebs; Isabelle Bartram; Helmut Blum; Monika Brüggemann; Jochen Hecht; Stefan K Bohlander; Philipp A Greif; Claudia D Baldus
Journal:  Oncotarget       Date:  2015-02-20
View more
  90 in total

Review 1.  Clonal hematopoiesis.

Authors:  Max Jan; Benjamin L Ebert; Siddhartha Jaiswal
Journal:  Semin Hematol       Date:  2016-10-20       Impact factor: 3.851

Review 2.  Aging and Hematopoiesis.

Authors:  Emma M Groarke; Neal S Young
Journal:  Clin Geriatr Med       Date:  2019-05-09       Impact factor: 3.076

3.  Leveraging premalignant biology for immune-based cancer prevention.

Authors:  Avrum Spira; Mary L Disis; John T Schiller; Eduardo Vilar; Timothy R Rebbeck; Rafael Bejar; Trey Ideker; Janine Arts; Matthew B Yurgelun; Jill P Mesirov; Anjana Rao; Judy Garber; Elizabeth M Jaffee; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-16       Impact factor: 11.205

4.  Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

Authors:  Eric J Duncavage; Geoffrey L Uy; Allegra A Petti; Christopher A Miller; Yi-Shan Lee; Bevan Tandon; Feng Gao; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Meagan A Jacoby; Amanda F Cashen; Lukas D Wartman; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley; John S Welch
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

5.  Managing Clonal Hematopoiesis in Patients With Solid Tumors.

Authors:  Kelly L Bolton; Nancy K Gillis; Catherine C Coombs; Koichi Takahashi; Ahmet Zehir; Rafael Bejar; Guillermo Garcia-Manero; Andrew Futreal; Brian C Jensen; Luis A Diaz; Dipti Gupta; Simon Mantha; Virginia Klimek; Elli Papaemmanuil; Ross Levine; Eric Padron
Journal:  J Clin Oncol       Date:  2018-11-07       Impact factor: 44.544

6.  Clinical significance of somatic mutation in unexplained blood cytopenia.

Authors:  Luca Malcovati; Anna Gallì; Erica Travaglino; Ilaria Ambaglio; Ettore Rizzo; Elisabetta Molteni; Chiara Elena; Virginia Valeria Ferretti; Silvia Catricalà; Elisa Bono; Gabriele Todisco; Antonio Bianchessi; Elisa Rumi; Silvia Zibellini; Daniela Pietra; Emanuela Boveri; Clara Camaschella; Daniela Toniolo; Elli Papaemmanuil; Seishi Ogawa; Mario Cazzola
Journal:  Blood       Date:  2017-04-19       Impact factor: 22.113

7.  Anaemia with inflammation responding to lenalidomide.

Authors:  Faysal Haroun; Andrew Mener; Jacob Elkon; Imad Tabbara
Journal:  BMJ Case Rep       Date:  2016-10-13

Review 8.  Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.

Authors:  Tamara K Moyo; Michael R Savona
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

9.  Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.

Authors:  Catherine C Coombs; Ahmet Zehir; Sean M Devlin; Ashwin Kishtagari; Aijazuddin Syed; Philip Jonsson; David M Hyman; David B Solit; Mark E Robson; José Baselga; Maria E Arcila; Marc Ladanyi; Martin S Tallman; Ross L Levine; Michael F Berger
Journal:  Cell Stem Cell       Date:  2017-08-10       Impact factor: 24.633

Review 10.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies.

Authors:  Robert L Bowman; Lambert Busque; Ross L Levine
Journal:  Cell Stem Cell       Date:  2018-02-01       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.